KR101678881B1 - 부작용을 가지지 않는 항암제 - Google Patents

부작용을 가지지 않는 항암제 Download PDF

Info

Publication number
KR101678881B1
KR101678881B1 KR1020157021404A KR20157021404A KR101678881B1 KR 101678881 B1 KR101678881 B1 KR 101678881B1 KR 1020157021404 A KR1020157021404 A KR 1020157021404A KR 20157021404 A KR20157021404 A KR 20157021404A KR 101678881 B1 KR101678881 B1 KR 101678881B1
Authority
KR
South Korea
Prior art keywords
cancer
irinotecan
dfp
group
dose
Prior art date
Application number
KR1020157021404A
Other languages
English (en)
Korean (ko)
Other versions
KR20150103749A (ko
Inventor
헤진 쳉
마사카주 푸쿠시마
키요시 에쉬마
개리 애쉴리
다니엘 브이. 산티
Original Assignee
데루타-후라이 화마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데루타-후라이 화마 가부시키가이샤 filed Critical 데루타-후라이 화마 가부시키가이샤
Publication of KR20150103749A publication Critical patent/KR20150103749A/ko
Application granted granted Critical
Publication of KR101678881B1 publication Critical patent/KR101678881B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020157021404A 2013-10-04 2014-02-07 부작용을 가지지 않는 항암제 KR101678881B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2013209574 2013-10-04
JPJP-P-2013-209574 2013-10-04
JP2013237219A JP5721806B2 (ja) 2013-10-04 2013-11-15 副作用のない抗癌剤
JPJP-P-2013-237219 2013-11-15
PCT/JP2014/052877 WO2015049883A1 (ja) 2013-10-04 2014-02-07 副作用のない抗癌剤

Publications (2)

Publication Number Publication Date
KR20150103749A KR20150103749A (ko) 2015-09-11
KR101678881B1 true KR101678881B1 (ko) 2016-11-23

Family

ID=52778484

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157021404A KR101678881B1 (ko) 2013-10-04 2014-02-07 부작용을 가지지 않는 항암제

Country Status (7)

Country Link
JP (1) JP5721806B2 (zh)
KR (1) KR101678881B1 (zh)
CN (1) CN104981245B (zh)
HK (1) HK1214145A1 (zh)
SG (2) SG10201703378UA (zh)
TW (1) TW201513863A (zh)
WO (1) WO2015049883A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3228650T3 (pl) 2014-12-04 2022-06-27 Delta-Fly Pharma, Inc. Nowa pochodna PEG
ES2965179T3 (es) 2020-05-14 2024-04-11 Delta Fly Pharma Inc Derivado polimérico soluble en agua de venetoclax

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505928A (ja) 2003-09-17 2007-03-15 ネクター セラピューティクス アラバマ，コーポレイション 多分岐ポリマーのプロドラッグ
JP2013511540A (ja) 2009-11-18 2013-04-04 ネクター セラピューティックス マルチアームポリマー−薬物コンジュゲートの塩形態
JP2013515791A (ja) 2009-12-25 2013-05-09 ジェンケム テクノロジー カンパニー リミテッド ティアンジンブランチ マルチアームポリエチレングリコール誘導体、マルチアームポリエチレングリコール誘導体と薬物との接合体およびゲル
JP2013528593A (ja) 2010-05-05 2013-07-11 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694776B2 (ja) 2003-07-29 2011-06-08 株式会社ヤクルト本社 微小粒子組成物又はリポソーム製剤
KR20120044925A (ko) * 2009-04-17 2012-05-08 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-가지 고분자 복합체를 이용한 신생혈관형성 억제 방법
KR20120104158A (ko) 2009-07-22 2012-09-20 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-히드록시캠토테신의 다분지형 중합 컨쥬게이트와 ｈｅｒ２ 수용체 길항제를 병용하여 ｈｅｒ２ 양성 암을 치료하는 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505928A (ja) 2003-09-17 2007-03-15 ネクター セラピューティクス アラバマ，コーポレイション 多分岐ポリマーのプロドラッグ
JP2013511540A (ja) 2009-11-18 2013-04-04 ネクター セラピューティックス マルチアームポリマー−薬物コンジュゲートの塩形態
JP2013515791A (ja) 2009-12-25 2013-05-09 ジェンケム テクノロジー カンパニー リミテッド ティアンジンブランチ マルチアームポリエチレングリコール誘導体、マルチアームポリエチレングリコール誘導体と薬物との接合体およびゲル
JP2013528593A (ja) 2010-05-05 2013-07-11 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放

Also Published As

Publication number Publication date
SG11201506026PA (en) 2015-09-29
CN104981245A (zh) 2015-10-14
JP2015091765A (ja) 2015-05-14
WO2015049883A1 (ja) 2015-04-09
SG10201703378UA (en) 2017-05-30
CN104981245B (zh) 2017-10-03
JP5721806B2 (ja) 2015-05-20
KR20150103749A (ko) 2015-09-11
HK1214145A1 (zh) 2016-07-22
TW201513863A (zh) 2015-04-16

Similar Documents

Publication Publication Date Title
RU2315782C2 (ru) Высокомолекулярные производные камптотецинов
US9801873B2 (en) Methods for treating humans having brain cancer
JP6223995B2 (ja) カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
CA3017690C (en) Oligolactic acid conjugates and micelles with enhanced anticancer efficacy
KR20170095811A (ko) 캄프토테신류 고분자 유도체의 의약 제제
KR101678881B1 (ko) 부작용을 가지지 않는 항암제
KR20170120568A (ko) 생리활성물질결합 블록 공중합체
US11806407B2 (en) Refillable drug delivery by affinity homing
JP6735759B2 (ja) カンプトテシン類高分子誘導体を含有する医薬組成物
US20150065443A1 (en) Embelin-based delivery system for water-insoluble active agents
TWI694838B (zh) 用於疏水性藥物傳送的新穎以聚合物爲基礎的增溶物
JP2011225510A (ja) 新規な抗腫瘍剤
US20220331437A1 (en) Conjugated inhibitors of dna damage response
JP6797182B2 (ja) カンプトテシン類高分子誘導体を含有する医薬製剤
WO2024030998A2 (en) Methods of treating cancer with long-acting topoisomerase i inhibitor

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
GRNT Written decision to grant